Saturday, June 13, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ONC”

274 pharma patents match "ONC" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 274
Index total 30,257
Page 3 / 12

Quick answer

This filtered view shows 274 pharmaceutical patents matching "ONC" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

274 results for “ONC” · 30,257 patents in full index Clear search

  1. US 11419934

    Use of VDAS to enhance immunomodulating therapies against tumors

    Oncotelic Therapeutics, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  2. US 11357795

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  3. US 11338003

    Methods of treating bladder cancer with an oncolytic virus

    CG ONCOLOGY, INC. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  4. US 11312786

    Oncofetal antigen binding proteins and related compositions and methods

    Aptevo Research and Development LLC · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  5. US 11298378

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  6. US 11291663

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  7. US 11285145

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Corcept Therapeutics Incorporated · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  8. US 11246930

    Reoviruses having modified sequences

    ONCOLYTICS BIOTECH INC. · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted
  9. US 11242380

    Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

    Takeda Pharmaceutical Company Limited · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  10. US 11229702

    High concentration formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  11. US 11207314

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  12. US 11208405

    Pyrrole derivatives as PLK1 inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  13. US 11207351

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  14. US 11202825

    Attenuated infectious bronchitis virus

    The Pirbright Institute · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted
  15. US 11202802

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted
  16. US 11191783

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  17. US 11166985

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  18. US 11135247

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted
  19. US 11124839

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  20. US 11117934

    Oncolytic virus platform to treat cancers with myxoma virus

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  21. US 11103552

    High concentration VEGF receptor fusion protein containing formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 31, 2021 · Expires Aug 26, 2041

    granted
  22. US 11077241

    Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combination with hyaluronic acid

    RegenLab USA LLC · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted
  23. US 11071755

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted
  24. US 11065285

    Biomarkers and combination therapies using oncolytic virus and immunomodulation

    The Board of Regents of the University of Texas System · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted